Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
64221-86-9
Molecular formula
C12H17N3O4S
Molecular weight
299.35 g/mol
Drug class
Carbapenem beta-lactam antibacterialused clinically with cilastatin
Mechanism of action
Binds penicillin-binding proteins and inhibits bacterial cell-wall peptidoglycan synthesis, producing bactericidal activity. Cilastatin inhibits renal dehydropeptidase-I and prevents renal metabolism of imipenem; the fixed combination is used for systemic antibacterial therapy.
Indications / reported uses
Treatment of serious infections caused by susceptible bacteria, including selected intra-abdominal, lower respiratory-tract, urinary-tract, gynaecological, skin/soft-tissue, bone/joint and septicaemia infections; current local antimicrobial guidance and susceptibility testing apply
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Imipenem PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Imipenem Permitted Daily Exposure (PDE) report (the Imipenem PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Imipenem Occupational Exposure Limit (OEL) report (the Imipenem OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.